Fortress Biotech Announces that its Subsidiary, Mustang Bio, Enters into License Agreements with City of Hope for Novel CAR T Immunotherapies Jun 05, 2017
Fortress Biotech Subsidiary Caelum Biosciences Enters Biopharmaceutical Manufacturing Agreement With Patheon Jun 01, 2017
Avenue Therapeutics Receives Notice of Allowance for a New Patent Application Covering Methods of Administration for Intravenous Tramadol May 19, 2017
Mustang Bio Reports First Quarter 2017 Financial Results and Recent Corporate Highlights May 15, 2017
Fortress Biotech Reports First Quarter 2017 Financial Results and Recent Corporate Highlights May 10, 2017
Fortress Biotech Announces Final Patient Dosed in Phase 1B Trial of CAEL-101 for the Treatment of AL Amyloidosis May 04, 2017
